https://www.live-feeds.com/feed/us-fda-approves-asahi-kasei-s-drug-for-persistent-herpes-infectionsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/us-fda-approves-asahi-kasei-s-drug-for-persistent-herpes-infectionshttps://www.live-feeds.com/feed/us-fda-approves-asahi-kasei-s-drug-for-persistent-herpes-infections#u135593Mon, 19 Oct 2026 11:10:30 +0000The US Food and Drug Administration approved Asahi Kasei's oral medication HOVILPRI, also known as pritelivir, to treat persistent herpes simplex virus sores. The treatment targets mucocutaneous lesions in immunocompromised adults that do not respond to standard antiviral treatments such as acyclovir, valacyclovir, or famciclovir. Developed as a helicase-primase inhibitor, the drug shifts resistant herpes care from intravenous methods to an oral daily pill. Asahi Kasei gained the therapy through its acquisition of German drugmaker AiCuris Anti-Infective Cures.Why it mattersStandard antivi